Welch Group’s Alaunos Therapeutics TCRT Stock Holding History

Welch Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-287	Closed	-$3.04K	–	244
2023 Q4	$3.04K	Hold	287	–	–	﹤0.01%	227
2023 Q3	$5.67K	Hold	287	–	–	﹤0.01%	213
2023 Q2	$21.9K	Hold	287	–	–	﹤0.01%	213
2023 Q1	$27.1K	Hold	287	–	–	﹤0.01%	212
2022 Q4	$27.9K	Sell	287 -104	-27%	-$15.1K	﹤0.01%	214
2022 Q3	$101K	Buy	391 +38	+11%	+$11K	0.01%	174
2022 Q2	$66K	Buy	353 +33	+10%	+$3.15K	﹤0.01%	196
2022 Q1	$31K	Hold	320	–	–	﹤0.01%	212
2021 Q4	$52K	Hold	320	–	–	﹤0.01%	214
2021 Q3	$87K	Hold	320	–	–	0.01%	187
2021 Q2	$127K	Hold	320	–	–	0.01%	189
2021 Q1	$173K	Hold	320	–	–	0.01%	188
2020 Q4	$121K	Hold	320	–	–	0.01%	146
2020 Q3	$121K	Hold	320	–	–	0.01%	137
2020 Q2	$157K	Hold	320	–	–	0.01%	130
2020 Q1	$118K	Buy	+320	New	+$166K	0.01%	145
2015 Q2	–	Sell	-158	Closed	-$256	–	150
2015 Q1	$256	Hold	158	–	–	0.05%	84
2014 Q4	$120K	Buy	+158	New	+$83.9K	0.02%	136

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Welch Group's TCRT Position: Q1 2024 in Review

Welch Group sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 287 shares — an estimated $3.04K sold.

Welch Group first reported a position in TCRT in Q4 2014 and held it in 18 quarters. The position peaked at $173K in Q1 2021. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Welch Group reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Welch Group sold 287 Alaunos Therapeutics shares in Q1 2024, an estimated $3.04K.
Welch Group first reported a position in Alaunos Therapeutics in Q4 2014 and held it in 18 quarters.
Welch Group's Alaunos Therapeutics position peaked at $173K in Q1 2021.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Welch Group's 13F filing for Q1 2024, filed 9 Apr 2024.